AVBP vs. AVTE, CALT, YMAB, IGMS, PHAT, GHRS, STOK, PHAR, ORIC, and ATXS
Should you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Aerovate Therapeutics (AVTE), Calliditas Therapeutics AB (publ) (CALT), Y-mAbs Therapeutics (YMAB), IGM Biosciences (IGMS), Phathom Pharmaceuticals (PHAT), GH Research (GHRS), Stoke Therapeutics (STOK), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
ArriVent BioPharma (NASDAQ:AVBP) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.
In the previous week, Aerovate Therapeutics had 19 more articles in the media than ArriVent BioPharma. MarketBeat recorded 26 mentions for Aerovate Therapeutics and 7 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.94 beat Aerovate Therapeutics' score of 0.46 indicating that ArriVent BioPharma is being referred to more favorably in the media.
9.5% of ArriVent BioPharma shares are held by institutional investors. 19.3% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
ArriVent BioPharma presently has a consensus target price of $29.25, indicating a potential upside of 45.52%. Aerovate Therapeutics has a consensus target price of $47.00, indicating a potential upside of 128.49%. Given Aerovate Therapeutics' higher probable upside, analysts plainly believe Aerovate Therapeutics is more favorable than ArriVent BioPharma.
Aerovate Therapeutics received 10 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 65.38% of users gave Aerovate Therapeutics an outperform vote.
ArriVent BioPharma's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.
Summary
ArriVent BioPharma beats Aerovate Therapeutics on 7 of the 11 factors compared between the two stocks.
Get ArriVent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ArriVent BioPharma Competitors List
Related Companies and Tools
